细胞质热休克蛋白 70 作为预测胶质母细胞瘤患者临床结局的生物标志物。

Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.

机构信息

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Institute of Pathology, Technical University of Munich, Munich, Germany.

出版信息

PLoS One. 2019 Aug 20;14(8):e0221502. doi: 10.1371/journal.pone.0221502. eCollection 2019.

INTRODUCTION

The major stress-inducible heat shock protein 70 (Hsp70) is induced after different stress stimuli. In tumors, elevated intracellular Hsp70 levels were associated on the one hand with radio- and chemotherapy resistance and on the other hand with a favorable outcome for patients. This study was undertaken to investigate cytosolic Hsp70 (cHsp70) as a potential biomarker for progression free (PFS) and overall survival (OS) in patients with primary glioblastomas (GBM).

METHODS

The cHsp70 expression in tumor tissue of 60 patients diagnosed with primary GBM was analyzed by immunohistochemistry. The cHsp70 expression was correlated to the PFS and OS of the patients.

RESULTS

A high cHsp70 expression was associated with a prolonged PFS (hazard ratio = 0.374, p = 0.001) and OS (hazard ratio = 0.416, p = 0.014) in GBM patients treated according to the standard Stupp protocol with surgery, radiotherapy and temozolomide.

CONCLUSIONS

These data suggest that the intracellular Hsp70 expression might serve as a prognostic marker in patients with primary GBM.

简介

主要的应激诱导热休克蛋白 70（Hsp70）在受到不同应激刺激后会被诱导产生。在肿瘤中，细胞内 Hsp70 水平的升高一方面与放射和化学疗法耐药有关，另一方面与患者的良好预后有关。本研究旨在探讨细胞质 Hsp70（cHsp70）作为原发性神经胶质瘤（GBM）患者无进展生存期（PFS）和总生存期（OS）的潜在生物标志物。